XEOMIN® Efficacy | Upper Limb Spasticity

Adults With Upper Limb Spasticity

Significant Difference Was Seen in the Mean Change on the Ashworth Scale Between XEOMIN and Placebo (P<0.001)1

  • Investigators evaluated 3 total primary target clinical patterns: flexed wrist, flexed elbow, or clenched fist1
  • XEOMIN patients showed significant improvement in muscle tone as measured by the Ashworth Scale vs placebo at week 41
    • Ashworth Scale is a clinical measure of the severity of spasticity by judging resistance to passive movement1
XEOMIN® demonstrated improvements in muscle tone. Pinch to zoom

*The analysis is based on last observation carried forward in the full analysis set.
P<0.001.

The Investigators’ Global Impression of Change Scale (GICS) Scores at Week 4 Demonstrated That XEOMIN Was Superior to Placebo1

  • XEOMIN patients had improvements in overall upper limb spasticity as measured by GICS1
    • GICS is a global measure of a patient’s functional improvement1
    • Investigators were asked to evaluate the patients‘ global change in spasticity of the upper limb due to treatment, compared to the condition before the last injection1
XEOMIN® improved patient’s functional improvement. Pinch to zoom

Reference

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.